Clinical Trials Directory

Trials / Completed

CompletedNCT00000232

Alternate Day Buprenorphine Administration, Phase IX - 14

Alternate Day Buprenorphine Administration, Phase IX

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
0 (planned)
Sponsor
University of Vermont · Academic / Other
Sex
All
Age
22 Years – 51 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.

Conditions

Interventions

TypeNameDescription
DRUGBuprenorphine

Timeline

Start date
1992-03-01
First posted
1999-09-21
Last updated
2016-05-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00000232. Inclusion in this directory is not an endorsement.